There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arrowhead Pharmaceuticals (ARWR – Research Report) and Fusion Pharmaceuticals (FUSN – Research Report) with bullish sentiments.
Arrowhead Pharmaceuticals (ARWR)
In a report issued on November 28, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals, with a price target of $83.00. The company’s shares closed last Wednesday at $32.20, close to its 52-week low of $26.81.
According to TipRanks.com, Issi ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Arrowhead Pharmaceuticals is a Strong Buy with an average price target of $61.38, which is a 100.5% upside from current levels. In a report issued on November 28, Robert W. Baird also maintained a Buy rating on the stock with a $60.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Fusion Pharmaceuticals (FUSN)
In a report released yesterday, Yuan Zhi from B.Riley Financial initiated coverage with a Buy rating on Fusion Pharmaceuticals and a price target of $10.00. The company’s shares closed last Wednesday at $2.27, close to its 52-week low of $1.98.
According to TipRanks.com, Zhi is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Fusion Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $9.00, representing a 286.3% upside. In a report released yesterday, SVB Securities also initiated coverage with a Buy rating on the stock with a $6.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARWR:
